Vijay has over thirty years of senior management experience in pharmaceutical services, medical devices and clinical diagnostics. He is currently Managing Partner of The Channel Group, LLC a life sciences venture development and management firm. He is also an active investor with the New York Angels and the Broad Street Angels. 

‍

Most recently, Dr. Aggarwal was President and CEO of Aureon Laboratories, Inc., a predictive pathology company offering advanced tissue analysis services to practicing physicians and the pharmaceutical industry. Previously, Dr. Aggarwal was CEO of Vaxigenix, a developer of immune treatments in oncology, CEO of InstantDx, one of the first e-prescription services, President of AAI Development Services, a global contract research organization and President of Quest Diagnostic Ventures, where he had responsibility for new technology, new business models, clinical trials testing, and direct–to-consumer strategies. 

‍

Earlier in his career, Dr. Aggarwal held many positions with SmithKline Beecham Clinical Laboratories, including direct responsibility for all of SBCL’s U.S.-based laboratories as Executive Vice President of Laboratories, for reimbursement as Vice President of Managed Care and as a Vice President in the Healthcare Services division of SmithKline Beecham. 

‍

As an active angel investor and advisor to venture capital organizations and as a CEO of venture backed companies, he has extensive experience in all aspects of early-stage company funding efforts. 

‍

He serves of the Boards of Accugenomics, Allergenis, Interpace Biosciences, Medcura (Observer) and Moleculera and is an advisor to Slone Partners. Dr. Aggarwal serves on the Boards of New York Angels and Broad Street Angels and is a member of M+A.

‍

He earned a BA in Chemistry from Case Western Reserve University and a Ph.D. in Pharmacology/Toxicology from the Medical College of Virginia.

‍